United Therapeutics Corporation - Common Stock (NQ:UTHR)

541.70 -29.68 (-5.19%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 to Keep Off Your Radar

June 13, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Biotech Stock With Strong Fundamentals and Attractive Valuation ↗

June 11, 2025

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong profitability, zero debt, and an undervalued stock price, making it a candidate for value investors in the biotech sector.

Via Chartmill

Dow Gains 50 Points; US Small Business Optimism Index Rises In May ↗

June 10, 2025

Via Benzinga

Topics Stocks

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia ↗

June 10, 2025

Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.

Via Investor's Business Daily

Forecasting The Future: 7 Analyst Projections For United Therapeutics ↗

June 02, 2025

Via Benzinga

Earnings Scheduled For April 30, 2025 ↗

April 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 10, 2025

Via Benzinga

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

May 29, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen...

Via StockStory

Topics Artificial Intelligence

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge ↗

May 27, 2025

Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics

Via Benzinga

Topics Intellectual Property

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors ↗

May 27, 2025

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and a cheap valuation, making it a standout for GARP investors following Peter Lynch's strategy.

Via Chartmill

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

May 26, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.

Via StockStory

Topics Artificial Intelligence

1 Safe-and-Steady Stock on Our Buy List and 2 to Ignore

May 19, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses

May 13, 2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers.

Via StockStory

Topics Artificial Intelligence

UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central

May 13, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its non-GAAP profit...

Via StockStory

Examining the Quality Attributes of UNITED THERAPEUTICS CORP (NASDAQ:UTHR). ↗

May 09, 2025

A fundamental analysis of (NASDAQ:UTHR): Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) qualifies as a quality stock.

Via Chartmill

3 Big Reasons to Love United Therapeutics (UTHR)

May 09, 2025

What a brutal six months it’s been for United Therapeutics. The stock has dropped 23.1% and now trades at $308, rattling many shareholders. This might have investors contemplating their next move.

Via StockStory

Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks

May 08, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex...

Via StockStory

Topics Artificial Intelligence

Following Peter Lynch’s approach: Does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fit the bill? ↗

May 05, 2025

Let’s dive into UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation.

Via Chartmill

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

May 02, 2025

See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024.

Via MarketBeat

Topics Regulatory Compliance

UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity ↗

May 01, 2025

UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity

Via Chartmill

1 Value Stock Worth Investigating and 2 to Brush Off

May 01, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1

April 30, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its GAAP profit of...

Via StockStory

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

April 30, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect

April 29, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.

Via StockStory

Topics Government World Trade

This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗

April 25, 2025

Via Benzinga

This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday ↗

April 25, 2025

Via Benzinga

Demystifying United Therapeutics: Insights From 4 Analyst Reviews ↗

April 25, 2025

Via Benzinga

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

April 21, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

April 16, 2025

From United Therapeutics Corporation

Via Business Wire

How does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) stack up against Peter Lynch’s investment principles? ↗

April 11, 2025

Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fits the characteristics of a...

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.